Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.
Atsuo Sasaki, PhD, a member of the CCC, the UC Cancer Institute and the UC Brain Tumor Center as well as an assistant professor in the division of hematology oncology within the department of internal medicine, is the principal investigator on the study, which is published in the online edition of the Journal of Biological Chemistry.
He says pharmacologic targeting of KRas as a cancer therapy has been challenging.
"The mutation of a KRas gene is an essential step in the development of many cancers," Sasaki says. "In fact, the KRas mutation is present in more than 90 percent of patients with pancreatic cancer, and other research has shown that lung and colon cancers have prevalent mutations of this gene as well.
"Researchers in academia and industry have been trying to target KRas pharmaceutically for many years without significant success. In this study, we took a unique approach. We use a social amoeboid - a powerful model system to study Ras signaling and look at the KRas regulation."
To do this, researchers introduced the oncogenic KRas gene into the social amoeboid and compared its regulation to that of a normal KRas gene.
"We discovered that the cell has a system to recognize the oncogenic KRas and break it down," he says. "This clearance system led to ubiquitination on oncogenic KRas - which means it is being chopped and trashed.
"With this knowledge, we could increase the clearance of mutated KRas from cancer cells; next steps include finding the gene or protein that starts this process. With this additional piece of the puzzle, we're one step closer to finding a targeted therapy for various cancer types that harbor KRas mutations."
This research was funded by grants from the UC Department of Internal Medicine and the Brain Tumor Center, which is part of the UC Neuroscience Institute.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
University of Cincinnati Academic Health Center. "Regulation of Cancer-Causing Protein Could Lead to New Therapeutic Targets." Medical News Today. MediLexicon, Intl., 20 Dec. 2013. Web.
25 Apr. 2014. <http://www.medicalnewstoday.com/releases/270308>
University of Cincinnati Academic Health Center. (2013, December 20). "Regulation of Cancer-Causing Protein Could Lead to New Therapeutic Targets." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/270308.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.